Jakafi: Medgend

Jakafi FDA Approved Drugs

JAKAFI [Ruxolitinib Phosphate^{C₁₇H₁₈N₆H₃O₄P}]

eq 10mg base (oral tablet)

eq 15mg base (oral tablet)

eq 20mg base (oral tablet)

eq 25mg base (oral tablet)

eq 5mg base (oral tablet)

Incyte Corp^{Nov 16, 2011}

For the treatment of intermediate or high-risk myelofibrosis.
For the treatment of polycythemia vera.
Use of ruxolitinib (jakafi) for blocking signal transduction of janus associated kinases (jaks) jak1 and/or jak2.
Use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2..

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.